Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.62 |
| ▸ | PKM | P14618 | 1/20 | 0.62 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.61 |
| ▸ | STS | P08842 | 3/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.60 |
| ▸ | MEN1 | O00255 | 5/20 | 0.60 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.56 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.56 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.56 |
| ▸ | CPB1 | P15086 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | MGLL | Q99685 | 1/20 | 0.53 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL407900 | 0.92 | KDM4E (0.56) | KDM4EPKMGPR119STSKMT2A | |
| SCHEMBL21848120 | 0.92 | KDM4E (0.56) | KDM4EPKMGPR119STSKMT2A | |
| SCHEMBL1156326 | 0.92 | KDM4E (0.56) | KDM4EPKMGPR119STSKMT2A | |
| SCHEMBL14113587 | 0.87 | KMT2A (0.71) | GPR119STSKMT2AMEN1PTPN2 | |
| SCHEMBL24833605 | 0.86 | MGLL (0.56) | GPR119STSKMT2APTPN2PTPN1 | |
| SCHEMBL473345 | 0.86 | STS (0.67) | STSKMT2AMEN1MGLLHSD11B1 | |
| SCHEMBL4235957 | 0.86 | MGLL (0.56) | GPR119STSKMT2APTPN2PTPN1 | |
| SCHEMBL18228469 | 0.86 | GPR119 (0.58) | KDM4EGPR119STSKMT2APTPN2 | |
| SCHEMBL228921 | 0.86 | HSD11B1 (0.63) | KDM4EKMT2AMEN1MGLLHSD11B1 | |
| SCHEMBL16395219 | 0.86 | KDM4E (0.59) | KDM4EPKMGPR119STSKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 112 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12576087-B2 | Aryloxypiperidine pyrazole compounds as indoleamine 2,3-dioxygenase inhibitors | MERCK SHARP & DOHME LLC (US) | 2026-03-17 | — | — | US | disclosed |
| US-11981661-B2 | Heterocyclic compounds | HOFFMANN-LA ROCHE INC. (US) | 2024-05-14 | — | — | US | disclosed |
| CN-111936503-B | Oxazine monoacylglycerol lipase (MAGL) inhibitors | 豪夫迈·罗氏有限公司 | 2023-09-12 | — | — | CN | disclosed |
| EP-4208456-A1 | HETEROCYCLIC COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2023-07-12 | — | — | EP | disclosed |
| US-20230117324-A1 | OXAZINE MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2023-04-20 | — | — | US | disclosed |
| CN-115989228-A | Heterocyclic compounds | 豪夫迈·罗氏有限公司 | 2023-04-18 | — | — | CN | disclosed |
| EP-3840747-B1 | NOVEL ARYLOXYPIPERIDINE PYRAZOLE COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2023-03-29 | — | — | EP | disclosed |
| EP-3768684-B1 | OXAZINE MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS | HOFFMANN LA ROCHE (CH) | 2023-02-22 | — | — | EP | disclosed |
| US-11420961-B2 | Heterocyclic compounds | HOFFMANN-LA ROCHE INC. (US) | 2022-08-23 | — | — | US | disclosed |
| EP-4034602-A1 | FLUORESCENT PROBES FOR MONOACYLGLYCEROL LIPASE (MAGL) | F. Hoffmann-La Roche AG (CH) | 2022-08-03 | — | — | EP | disclosed |
| EP-1408037-A1 | Novel diarylmethylpiperazine and diarylmethylphenyl compounds with analgesic effect | AstraZeneca AB (SE) | 2004-04-14 | — | — | EP | disclosed |
| US-6680321-B1 | 4-((1-PIPERAZINYLMETHYL)-BENZAMIDE DERIVATIVES; HYPOTENSIVE AGENTS; IMMUNOMODULATORS | ASTRAZENECA CANADA, INC. (CA) | 2004-01-20 | — | — | US | disclosed |
| WO-2003082278-A1 | THIAZOLIDINE CARBOXAMIDE DERIVATIVES AS MODULATORS OF THE PROSTAGLANDIN F RECEPTOR | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2003-10-09 | — | — | WO | disclosed |
| CN-1119336-C | Novel compounds with analgesic action | ASTRA PHARMA INC (CA) | 2003-08-27 | — | — | CN | disclosed |
| WO-2003068807-A2 | ECHINOCANDIN CYCLIC PEPTIDE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-08-21 | — | — | WO | disclosed |
| WO-2003033495-A1 | QUINUCLIDINE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES AS M2 AND/OR M3 MUSCARINIC RECEPTOR INHIBITORS | UCB, S.A. (BE) | 2003-04-24 | — | — | WO | disclosed |
| US-6130222-A | Compounds with analgesic effect | ASTRA PHARMA INC. (CA) | 2000-10-10 | — | — | US | disclosed |
| EP-0915855-A1 | NOVEL COMPOUNDS WITH ANALGESIC EFFECT | Astra Pharma Inc. (CA) | 1999-05-19 | — | — | EP | disclosed |
| CN-1209124-A | Novel compounds with analgesic effect | ASTRA PHARMA INC (CA) | 1999-02-24 | — | — | CN | disclosed |
| WO-1997023466-A1 | NOVEL COMPOUNDS WITH ANALGESIC EFFECT | ASTRA PHARMA INC. (CA) | 1997-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12576087-B2 | Aryloxypiperidine pyrazole compounds as indoleamine 2,3-dioxygenase inhibitors | IDO1, IDO2, TPH1 | KDM4E 1711/4885PKM 3146/4885GPR119 369/4885 |
| US-11981661-B2 | Heterocyclic compounds | CBR3, BRIX1, CCNY | KDM4E 1570/4885PKM 2111/4885GPR119 2316/4885 |
| US-11420961-B2 | Heterocyclic compounds | LPXN, MLX, CCNY | KDM4E 1597/4885PKM 1247/4885GPR119 3037/4885 |
| US-20230117324-A1 | OXAZINE MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS | MGLL, LPL, LIPC | KDM4E 1888/4885PKM 2165/4885GPR119 432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.